PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the ...
Detransitioner Fox Varian's $2 million jury verdict represents an existential threat to the transgender child mutilation pipeline.
Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results